INmune Bio shares surge 18.03% premarket after MINDFuL trial highlights biomarker-enriched Alzheimer's drug success.

INmune Bio surged 18.03% in premarket trading following the announcement that its Phase 2 MINDFuL trial of XPro1595 (pegipanermin) was highlighted in a plenary presentation at AD/PD 2026, a leading Alzheimer’s and Parkinson’s conference. The trial, which demonstrated consistent efficacy signals in an inflamed patient subgroup, was praised for aligning inflammatory biomarker enrichment with the drug’s mechanism of action, a strategy endorsed by neurology expert Dr. Malú Gámez Tansey. The company also reported positive alignment with the FDA to advance an integrated Phase 2b/3 registrational program for biomarker-enriched early Alzheimer’s patients. The presentation underscored XPro1595’s potential as a precision therapy targeting peripheral inflammation, a key driver of neurodegeneration, and reinforced investor confidence in the drug’s development pathway.